FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4301394218> ?p ?o ?g. }

• W4301394218 endingPage "103877" @default.
• W4301394218 startingPage "103877" @default.
• W4301394218 abstract "The coronavirus pandemic resulted in many changes which had the potential to impact mortality related to opioid agonist therapy (OAT; methadone, buprenorphine), including changes in the prescribing and dispensing of OAT and patterns of drug availability and use. We aimed to assess the impact of the first lockdown (initiated March 23rd 2020) on methadone- and buprenorphine-related deaths in England in people both prescribed and not prescribed OAT using data from the National Programme on Substance Abuse Deaths. This was a retrospective post-mortem toxicology study of OAT-related deaths which occurred in the 3-month period March 23rd to June 22nd in the years 2016-2020. Provisional data regarding numbers accessing treatment for opioid use disorder was provided by the National Drug Treatment Monitoring System. We found a 64% increase in methadone-related deaths in March to June 2020 compared to March to June 2019 (2019 n = 96; 2020 projected n = 157). There were increases in the mortality rate of both in-treatment decedents (22% increase; 2019 n = 45; an exponential smoothing model of the 2016-19 trend [α=0.5] predicted 44 deaths in 2020, 55 were reported) and decedents not prescribed methadone (74% increase; 2019 n = 46; 2016-19 trend predicted 43 deaths in 2020, 80 were reported). There was no increase in buprenorphine-related deaths (2019 n = 9/529; 2020 n = 11/566). There were no changes in the numbers of deaths where other opioids or multiple substances were detected, or in methadone levels detected. Numbers of people accessing treatment for opioid use disorder in 2020 did not decrease relative to previous years (p >0.05). Methadone-related deaths in non-prescribed individuals, but not prescribed individuals, increased considerably above the annual trend forecast for 2020 during the first COVID-19 lockdown in England. Further studies are thus needed to understand this difference." @default.
• W4301394218 created "2022-10-05" @default.
• W4301394218 creator A5015521194 @default.
• W4301394218 creator A5034187661 @default.
• W4301394218 creator A5044143492 @default.
• W4301394218 creator A5047884739 @default.
• W4301394218 creator A5060812676 @default.
• W4301394218 creator A5063343220 @default.
• W4301394218 creator A5077203130 @default.
• W4301394218 date "2022-12-01" @default.
• W4301394218 modified "2023-10-03" @default.
• W4301394218 title "Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England" @default.
• W4301394218 cites W1538393289 @default.
• W4301394218 cites W1900525091 @default.
• W4301394218 cites W1906991930 @default.
• W4301394218 cites W1968029665 @default.
• W4301394218 cites W1995139905 @default.
• W4301394218 cites W2024713748 @default.
• W4301394218 cites W2035396616 @default.
• W4301394218 cites W2256268805 @default.
• W4301394218 cites W2583544080 @default.
• W4301394218 cites W2608446001 @default.
• W4301394218 cites W3015199197 @default.
• W4301394218 cites W3016822260 @default.
• W4301394218 cites W3041488668 @default.
• W4301394218 cites W3080352857 @default.
• W4301394218 cites W3087556578 @default.
• W4301394218 cites W3091538283 @default.
• W4301394218 cites W3092563374 @default.
• W4301394218 cites W3106187707 @default.
• W4301394218 cites W3110353292 @default.
• W4301394218 cites W3120077942 @default.
• W4301394218 cites W3120576161 @default.
• W4301394218 cites W3127060520 @default.
• W4301394218 cites W3133329368 @default.
• W4301394218 cites W3133771337 @default.
• W4301394218 cites W3138890370 @default.
• W4301394218 cites W3139402078 @default.
• W4301394218 cites W3167036024 @default.
• W4301394218 cites W3184829782 @default.
• W4301394218 cites W3186009275 @default.
• W4301394218 cites W3193124358 @default.
• W4301394218 cites W3201145434 @default.
• W4301394218 cites W3203085139 @default.
• W4301394218 cites W3205368003 @default.
• W4301394218 cites W3214534939 @default.
• W4301394218 cites W4200017130 @default.
• W4301394218 cites W4214697512 @default.
• W4301394218 cites W4214724411 @default.
• W4301394218 cites W4221023870 @default.
• W4301394218 cites W4226047672 @default.
• W4301394218 cites W4285084523 @default.
• W4301394218 cites W4288042130 @default.
• W4301394218 cites W4291951007 @default.
• W4301394218 doi "https://doi.org/10.1016/j.drugpo.2022.103877" @default.
• W4301394218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36265326" @default.
• W4301394218 hasPublicationYear "2022" @default.
• W4301394218 type Work @default.
• W4301394218 citedByCount "14" @default.
• W4301394218 countsByYear W43013942182023 @default.
• W4301394218 crossrefType "journal-article" @default.
• W4301394218 hasAuthorship W4301394218A5015521194 @default.
• W4301394218 hasAuthorship W4301394218A5034187661 @default.
• W4301394218 hasAuthorship W4301394218A5044143492 @default.
• W4301394218 hasAuthorship W4301394218A5047884739 @default.
• W4301394218 hasAuthorship W4301394218A5060812676 @default.
• W4301394218 hasAuthorship W4301394218A5063343220 @default.
• W4301394218 hasAuthorship W4301394218A5077203130 @default.
• W4301394218 hasBestOaLocation W43013942181 @default.
• W4301394218 hasConcept C118552586 @default.
• W4301394218 hasConcept C126322002 @default.
• W4301394218 hasConcept C144024400 @default.
• W4301394218 hasConcept C149923435 @default.
• W4301394218 hasConcept C167135981 @default.
• W4301394218 hasConcept C170493617 @default.
• W4301394218 hasConcept C194828623 @default.
• W4301394218 hasConcept C2778767360 @default.
• W4301394218 hasConcept C2778903686 @default.
• W4301394218 hasConcept C2778949969 @default.
• W4301394218 hasConcept C2779134260 @default.
• W4301394218 hasConcept C2779418921 @default.
• W4301394218 hasConcept C2780035454 @default.
• W4301394218 hasConcept C2781063702 @default.
• W4301394218 hasConcept C3008058167 @default.
• W4301394218 hasConcept C40010229 @default.
• W4301394218 hasConcept C42219234 @default.
• W4301394218 hasConcept C524204448 @default.
• W4301394218 hasConcept C71924100 @default.
• W4301394218 hasConcept C89623803 @default.
• W4301394218 hasConceptScore W4301394218C118552586 @default.
• W4301394218 hasConceptScore W4301394218C126322002 @default.
• W4301394218 hasConceptScore W4301394218C144024400 @default.
• W4301394218 hasConceptScore W4301394218C149923435 @default.
• W4301394218 hasConceptScore W4301394218C167135981 @default.
• W4301394218 hasConceptScore W4301394218C170493617 @default.
• W4301394218 hasConceptScore W4301394218C194828623 @default.
• W4301394218 hasConceptScore W4301394218C2778767360 @default.
• W4301394218 hasConceptScore W4301394218C2778903686 @default.

• next